

ABSTRACT

Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0 - 70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail* in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

4/6/98 BY Martin W. Schiffmiller
(date) Martin W. Schiffmiller
Reg. No. 30,421

*EM485478381US